Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 4/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.42 |
| ▸ | CLK2 | P49760 | 7/20 | 0.42 |
| ▸ | CLK3 | P49761 | 6/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.38 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149599 | 0.91 | MAP2K4 (0.52) | MAP2K4MAP4K1CLK2CLK3DYRK1A | |
| SCHEMBL4146121 | 0.83 | CLK2 (0.46) | MAP2K4MAP4K1CLK2CLK3DYRK1A | |
| SCHEMBL5032419 | 0.81 | SCN9A (0.46) | MAP2K4MAP4K1CLK2CLK3DYRK1A | |
| SCHEMBL27623648 | 0.80 | CLK2 (0.45) | MAP2K4MAP4K1CLK2CLK3DYRK1A | |
| SCHEMBL4136209 | 0.80 | EGLN1 (0.41) | MAP2K4MAP4K1CLK2CLK3DYRK1A | |
| SCHEMBL5031128 | 0.78 | SCN9A (0.48) | MAP2K4CLK2CLK3DYRK1A | |
| SCHEMBL13927643 | 0.77 | MAP4K4 (0.46) | MAP2K4MAP4K1CLK2CLK3DYRK1A | |
| SCHEMBL5029950 | 0.77 | SCN9A (0.44) | — | |
| SCHEMBL4149434 | 0.77 | DYRK1A (0.52) | MAP2K4CLK2CLK3DYRK1A | |
| SCHEMBL4149829 | 0.76 | ADORA3 (0.57) | MAP2K4MAP4K1CLK2CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | OHI NORIHITO | 2009-02-26 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054397-A1 | PYRAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND | CNKSR1, NR3C2, CSNK2B | MAP2K4 48/4885MAP4K1 79/4885CLK2 125/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | MAP2K4 54/4885MAP4K1 74/4885CLK2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.